Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;105(12):3381-3388.
doi: 10.1016/j.pec.2022.08.005. Epub 2022 Aug 18.

Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review

Affiliations
Review

Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review

Allison A Lewinski et al. Patient Educ Couns. 2022 Dec.

Abstract

Objective: Clinical inertia, the absence of treatment initiation or intensification for patients not achieving evidence-based therapeutic goals, is a primary contributor to poor clinical outcomes. Effectively combating clinical inertia requires coordinated action on the part of multiple representatives including patients, clinicians, health systems, and the pharmaceutical industry. Despite intervention attempts by these representatives, barriers to overcoming clinical inertia in cardiovascular disease (CVD) risk factor control remain.

Methods: We conducted a narrative literature review to identify individual-level and multifactorial interventions that have been successful in addressing clinical inertia.

Results: Effective interventions included dynamic forms of patient and clinician education, monitoring of real-time patient data to facilitate shared decision-making, or a combination of these approaches. Based on findings, we describe three possible multi-level approaches to counter clinical inertia - a collaborative approach to clinician training, use of a population health manager, and use of electronic monitoring and reminder devices.

Conclusion: To reduce clinical inertia and achieve optimal CVD risk factor control, interventions should consider the role of multiple representatives, be feasible for implementation in healthcare systems, and be flexible for an individual patient's adherence needs.

Practice implications: Representatives (e.g., patients, clinicians, health systems, and the pharmaceutical industry) could consider approaches to identify and monitor non-adherence to address clinical inertia.

Keywords: Cardiovascular disease; Clinical inertia; Diabetes mellitus; Disease management; Medication adherence; Treatment outcome.

PubMed Disclaimer

Conflict of interest statement

Competing interests Dr. Zullig reports research grant support from the PhRMA Foundation, and Proteus Digital Health and consulting from Novartis and Pfizer. Dr. Lewinski reports research support from PhRMA Foundation and Otsuka. Drs. Goldstein and Jazowski report no conflicts of interest. Dr. Bosworth reports research grants from Sanofi, PhRMA Foundation, Proteus Digital Health, Otsuka, Novo Nordisk, Improved Patient Outcomes, Boehringer Ingelheim as well as consulting from Otsuka, Abbott, Walmart, Better therapeutics, VIDYA, and Sanofi.

Figures

Figure 1.
Figure 1.
PRISMA Diagram Note: The search was conducted in two phases. Phase 1 included articles from 01/2014 to 01/2019 and Phase 2 included articles from 01/2019 to 06/2021. Both searches followed the same methodological processes.
Figure 2.
Figure 2.
Components of Three Proposed Multi-Level Interventions to Counter Clinical Inertia

Similar articles

Cited by

References

    1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American College of Cardiology. 2020;76(25):2982–3021. - PMC - PubMed
    1. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020;75(2):285–292. - PMC - PubMed
    1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology. 2018;17(1):83. - PMC - PubMed
    1. Kim EJ, Wierzbicki AS. Cardiovascular prevention: Frontiers in lipid guidelines. Clinical medicine (London, England). 2020;20(1):36–42. - PMC - PubMed
    1. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Medical care. 2004;42(3):200–209. - PubMed

Publication types